BLACK DIAMOND THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 31.50K shares, a 70.65% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 41.17K shares, a 129.61% increase year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-12-31 was 107.34K shares.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-09-30 was 17.93K shares.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 85.27K shares, a 75.06% decline from fiscal 2024.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 341.98K shares, a 6268.40% increase from fiscal 2023.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 5.37K shares, a 7.98% increase from fiscal 2022.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 4.97K shares, a 95.50% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 31.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | 85.27K shares 10-K · filed 2026-03-16 |
| 2025-09-30 | 41.17K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | |
| 2024-12-31 | 107.34K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 341.98K shares 10-K · filed 2025-03-06 |
| 2024-09-30 | 17.93K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | 234.64K shares derived: sum of 4 quarters · filed 2024-11-05 |
| 2024-06-30 | 168.97K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | |
| 2024-03-31 | 47.74K shares 10-Q · filed 2024-05-09 | |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | 5.37K shares 10-K · filed 2024-03-12 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | 4.97K shares 10-K · filed 2023-03-09 |
| 2022-09-30 | 1.41K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 4.97K shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 3.56K shares derived: sum of 4 quarters · filed 2022-08-09 |
| 2022-03-31 | 3.56K shares 10-Q · filed 2022-05-11 | 51.58K shares derived: sum of 4 quarters · filed 2022-05-11 |
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | 110.62K shares 10-K · filed 2022-03-17 |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | 220.05K shares derived: sum of 4 quarters · filed 2021-11-08 |
| 2021-06-30 | 48.01K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | |
| 2021-03-31 | 62.61K shares 10-Q · filed 2021-05-07 | |
| 2020-12-31 | 109.43K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | 160.51K shares 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |